Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Mesoblast, Ltd.
Age
0–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient must have one of the following:
* Acute myelogenous leukemia (AML) in complete morphological remission at study screening (Complete Remission with Incomplete Platelet Recovery (CRp) acceptable).
* Acute lymphoblastic leukemia (ALL) in complete morphological remission at study screening (Complete Remission with Incomplete Platelet Recovery (CRp) acceptable).
* Non-Hodgkin's lymphoma (NHL): High risk subjects with responsive disease after first relapse. High risk includes those with Burkitt's Lymphoma and those with extensive marrow involvement at diagnosis-precluding autologous transplant.
* Hodgkin's disease: High risk subjects with responsive disease after first relapse.
Minimum Karnofsky Scale
Subject must weigh at least 20 kg
Up to 65 years of age
Adequate major organ system function
You may not be if
Pregnancy and/or lactating
Suitable, 6/6 HLA matched related sibling donor available
Previous participation in a stem cell study within last 30 days
Clareo Health | P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
